MPLTMapLight Therapeutics, Inc.
$8.83
$8.83
$8.8352 weeks$39.24
MPLT in its own filings
Nothing in MPLT's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
19
Events found in the filings · across 196 filings · the record starts in 2024
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 13, 2026
Most recent filing · Form 10-Q
- Record starts
- Apr 4, 2024
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Dec 3, 2026
- SEC comment-letter activity3 occurrences
- 2025-08-12
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 13, 2026On August 13, 2026, MapLight Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (the “Private …Material agreement entered · Form 8-K
- Jul 27, 2026On July 27, 2026, the Company issued a press release announcing the ZEPHYR Trial Results.Regulation FD disclosure · Form 8-K
- Jun 22, 2026On June 22, 2026, the Company issued a press release announcing the IRIS Trial Results.Regulation FD disclosure · Form 8-K
- Jun 18, 2026On June 18, 2026, Vishwas Setia was separated as the Chief Financial Officer of MapLight Therapeutics, Inc. (the “Company”), effective immediately, following a review of a human resources violation.Director or officer change · Form 8-K
- May 14, 2026MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Apr 29, 2026On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the “Board”) of MapLight Therapeutics, Inc. (the “Company”) of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.Director or officer change · Form 8-K
- Mar 26, 2026MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
- Jan 9, 2026ML-007C-MA Lead Asset in Development for Schizophrenia and ADP.Earnings release · press release
- Dec 4, 2025MapLight Therapeutics Reports Third Quarter Financial Results and.Earnings release · press release
- Oct 29, 2025On October 26, 2025, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Jefferies LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein (collectively, the “Underwriters”), in …Unregistered sale of equity · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Biotechnology
The closest names by size in the same industry